Researches on the Mechanism of Overexpression of Tripartite Motif Protein 48 Regulating p-ERK1/2 to Inhibit Glioma Growth
-
摘要:
目的 探究过表达三结构域蛋白48(tripartite motif protein,TRIM)对胶质瘤生长的影响及其相关机制。 方法 将12只裸鼠随机均分为2组,分别接种过表达TRIM48的U87胶质瘤稳转株(oeTRIM48组)及其对照细胞株(Vector组)。接种后每3 d测定肿瘤体积,4周后取出肿瘤组织并记录瘤重。肿瘤组织做HE染色,并通过免疫荧光法检测Ki-67的表达,使用Western blot和免疫组化分别检测裸鼠肿瘤和人胶质瘤组织芯片中的TRIM48、ERK1/2和p-ERK1/2水平。 结果 oeTRIM48组裸鼠肿瘤体积、重量比Vector组裸鼠明显降低(P < 0.0001);HE染色结果显示oeTRIM48组细胞核减小、核分裂象减少;Ki-67阳性区域显著降低(P < 0.0001),而且oeTRIM48组p-ERK1/2蛋白水平比Vector组显著降低(P < 0.01)。组织芯片免疫组化显示,TRIM48和p-ERK1/2在癌旁组织分别呈高表达和低表达,在肿瘤组织则相反。 结论 过表达TRIM48能够抑制胶质瘤生长、增殖,其作用机制可能与ERK1/2信号通路有关。 Abstract:Objective To investigate the impact of TRIM48 overexpression on glioma and explore the underlying mechanism. Methods Twelve nude mice were randomly assigned into two groups: one inoculated with U87 glioma cells stably overexpressing TRIM48 (oeTRIM48 group) and the other with the control cell line (Vector group). Tumor volume was measured every 3 days post-inoculation, and after 4 weeks, the tumors were excised and weighed. Tumor tissues underwent hematoxylin and eosin (H&E) staining, and Ki-67 expression was assessed using immunofluorescence. Additionally, the expressions of TRIM48, ERK1/2, and phosphorylated ERK1/2 (p-ERK1/2) in the tumors of nude mice and human glioma tissue arrays were analyzed through Western blot and immunohistochemistry respectively. Results Compared to the Vector group, the oeTRIM48 group exhibited significantly reduced tumor volume and weight (P < 0.0001). H&E staining indicated a decrease in nuclei and mitotic count in the oeTRIM48 group. Furthermore, Ki-67 expression was significantly lower in the oeTRIM48 group than that in the Vector group (P < 0.0001). The oeTRIM48 group also showed a significantly lower expression of p-ERK1/2 protein compared to the Vector group (P < 0.01). Immunohistochemistry on tissue microarrays revealed the high expression of TRIM48 and low expression of p-ERK1/2 in adjacent non-tumoral tissues, with the opposite pattern observed in tumor tissues. Conclusion Overexpression of TRIM48 inhibits the growth and proliferation of glioma, potentially through modulation of the ERK1/2 signaling pathway. -
表 1 PCR引物
Table 1. PCR primers
引物名称 目的基因 序列(5'→3') 产物大小(bp) Forward primer 1 TRIM48 AGCACCGGTATCACAGACAC 162 Reverse primer 1 TRIM48 TGTCTCCAAAAGCCTTCCAGTG 162 Forward primer 2 β-actin AGGATTCCTATGTGGGCGAC 273 Reverse primer 2 β-actin ATAGCACAGCCTGGATAGCAA 273 -
[1] Omuro A,DeAngelis L M. Glioblastoma and other malignant gliomas: A clinical review[J]. Jama,2013,310(17):1842-1850. doi: 10.1001/jama.2013.280319 [2] 国家卫生健康委员会医政医管局,中国抗癌协会脑胶质瘤专业委员会,中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022版)[J]. 中华神经外科杂志,2022,38(8):757-777. doi: 10.3760/cma.j.cn112050-20220510-00239 [3] Ostrom Q T,Bauchet L,Davis F G,et al. The epidemiology of glioma in adults: A "state of the science" review[J]. Neuro Oncol,2014,16(7):896-913. doi: 10.1093/neuonc/nou087 [4] Schaff L R,Mellinghoff I K. Glioblastoma and other primary brain malignancies in adults: A review[J]. Jama,2023,329(7):574-587. [5] Ozato K,Shin D M,Chang T H,et al. TRIM family proteins and their emerging roles in innate immunity[J]. Nat Rev Immunol,2008,8(11):849-860. doi: 10.1038/nri2413 [6] Hatakeyama S. TRIM proteins and cancer[J]. Nat Rev Cancer,2011,11(11):792-804. doi: 10.1038/nrc3139 [7] Watanabe M,Hatakeyama S. TRIM proteins and diseases[J]. J Biochem,2017,161(2):135-144. [8] Menon S,Goldfarb D,Ho C T,et al. The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis[J]. Mol Biol Cell,2021,32(4):314-330. doi: 10.1091/mbc.E20-10-0622 [9] Montell D J. TRIMing neural connections with ubiquitin[J]. Dev Cell,2019,48(1):5-6. doi: 10.1016/j.devcel.2018.12.012 [10] Magiera M M,Mora S,Mojsa B,et al. Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons[J]. Cell Death Differ,2013,20(2):281-292. doi: 10.1038/cdd.2012.124 [11] Venuto S,Castellana S,Monti M,et al. TRIM8-driven transcriptomic profile of neural stem cells identified glioma-related nodal genes and pathways[J]. Biochim Biophys Acta Gen Subj,2019,1863(2):491-501. doi: 10.1016/j.bbagen.2018.12.001 [12] Zhang C,Mukherjee S,Tucker-Burden C,et al. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3[J]. Mol Oncol,2017,11(3):280-294. doi: 10.1002/1878-0261.12034 [13] Deng Y,Zhu H,Xiao L,et al. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis[J]. Aging (Albany NY),2020,13(2):2198-2211. [14] Meng L,Wang Y,Tu Q,et al. Circular RNA circ_0000741/miR-379-5p/TRIM14 signaling axis promotes HDAC inhibitor (SAHA) tolerance in glioblastoma[J]. Metab Brain Dis,2023,38(4):1351-1364. [15] Zhang L H,Yin Y H,Chen H Z,et al. TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression[J]. Neuro Oncol,2020,22(12):1797-1808. doi: 10.1093/neuonc/noaa138 [16] Han K,Lou D I,Sawyer S L. Identification of a genomic reservoir for new TRIM genes in primate genomes[J]. PLoS Genet,2011,7(12):e1002388. doi: 10.1371/journal.pgen.1002388 [17] Xue L P,Lu B,Gao B B,et al. Overexpression of tripartite motif-containing 48 (TRIM48) inhibits growth of human glioblastoma cells by suppressing extracellular signal regulated kinase 1/2 (ERK1/2) pathway[J]. Med Sci Monit,2019,25(1):8422-8429. [18] Jin Q,Zhang W,Qiu X G,et al. Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma[J]. Chin Med J (Engl),2011,124(17):2584-2588. [19] Yang P,Wang Y,Peng X,et al. Management and survival rates in patients with glioma in China (2004-2010): A retrospective study from a single-institution[J]. J Neurooncol,2013,113(2):259-266. doi: 10.1007/s11060-013-1103-9 [20] Sun X,Kaufman P D. Ki-67: More than a proliferation marker[J]. Chromosoma,2018,127(2):175-186. doi: 10.1007/s00412-018-0659-8 [21] Cuylen S,Blaukopf C,Politi A Z,et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes[J]. Nature,2016,535(7611):308-312. doi: 10.1038/nature18610 [22] Mrouj K,Andr é s-S á nchez N,Dubra G,et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis[J]. Proc Natl Acad Sci USA,2021,118(10):e2026507118. doi: 10.1073/pnas.2026507118 [23] Theresia E,Malueka R G,Pranacipta S,et al. Association between Ki-67 labeling index and histopathological grading of glioma in indonesian population[J]. Asian Pac J Cancer Prev,2020,21(4):1063-1068. doi: 10.31557/APJCP.2020.21.4.1063 [24] Yu Z,Ye S,Hu G,et al. The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles to effective cancer therapy[J]. Future Med Chem,2015,7(3):269-289. doi: 10.4155/fmc.14.143 [25] Bhattacharya D,Chaudhuri S,Singh M K,et al. T11TS inhibits angiopoietin-1/Tie-2 signaling,EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model[J]. Exp Mol Pathol,2015,98(3):455-466. doi: 10.1016/j.yexmp.2015.03.026 [26] Cheng M,Liu L. MUC15 promotes growth and invasion of glioma cells by activating Raf/MEK/ERK pathway[J]. Clin Exp Pharmacol Physiol,2020,47(6):1041-1048. doi: 10.1111/1440-1681.13277 [27] Li Q,Zhang L,Yang Q,et al. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners[J]. Cell Metab,2023,35(6):912-927. doi: 10.1016/j.cmet.2023.03.017 [28] Hirata Y. Reactive oxygen species (ROS) signaling: Regulatory mechanisms and pathophysiological roles[J]. Yakugaku Zasshi,2019,139(10):1235-1241. doi: 10.1248/yakushi.19-00141 [29] Hirata Y,Katagiri K,Nagaoka K,et al. TRIM48 promotes ASK1 activation and cell death through ubiquitination-dependent degradation of the ASK1-negative regulator PRMT1[J]. Cell Rep,2017,21(9):2447-2457. doi: 10.1016/j.celrep.2017.11.007